Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move? Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?
Tuesday's session: gap up and gap down stocks In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
Wondering what's happening in today's pre-market session? The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.
SLDB Stock Earnings: Solid Biosciences Beats EPS for Q2 2024 SLDB stock results show that Solid Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease.
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom.
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation.
SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024 SLDB stock results show that Solid Biosciences met analyst estimates for earnings per share the first quarter of 2024.
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.
